A Review of the Treatment for Multiple Myeloma

A panel of experts lead by Dr. Keith Stewart, MB, ChB, discuss the current treatment landscape of multiple myeloma.

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Biochemical Versus Symptomatic Relapse Treatment Choices in MM
October 17, 2019 – 
Sundar Jagannath, MD, shares his approach to choosing the best treatment plan for patients based on genetic risk in multiple myeloma.
Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma
October 17, 2019 – 
The key opinion leaders discuss the need for transparency between the National Comprehensive Cancer Network (NCCN) guidelines, payer preference, and real-world patient needs in multiple myeloma.
Patient Cost Implications in Multiple Myeloma Treatment
October 11, 2019 – 
The influence of patient cost on choosing an outpatient versus inpatient treatment option are explored in the management of multiple myeloma.
Treatment Options in Relapsed/Refractory Multiple Myeloma
October 11, 2019 – 
Sundar Jagannath, MD, emphasizes an individualized treatment approach for relapsed/refractory multiple myeloma.
Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma
October 07, 2019 – 
Panelists discuss the reimbursement of subcutaneous versus intravenous (IV) dosing and the implications for patients with multiple myeloma.
OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma
October 07, 2019 – 
A discussion of the Oncology Care Model (OCM) goals to ensure better outcomes for patients with multiple myeloma leads to better cost savings.
The Impact of OCM in the Treatment of Multiple Myeloma
September 27, 2019 – 
A review of the potential impact of the Oncology Care Model (OCM) on the treatment of multiple myeloma.
Entering a 4-Drug Regimen for Multiple Myeloma Treatment
September 27, 2019 – 
The panel discusses the future of 4-drug combinations for the treatment of multiple myeloma, including the GRIFFIN trial.
MAIA Trial: Transplant-Ineligible Patients With MM
September 20, 2019 – 
Experts delve into evolving standards of care for patients who are not eligible for transplant in multiple myeloma treatment and discuss the outcomes of the MAIA trial.
Using MRD Negativity to Stop Maintenance Therapy in MM
September 20, 2019 – 
A discussion on the goal of minimal residual disease (MRD) negativity and when is it appropriate to continue or discontinue treatment.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.